Transient Removal of CD46 Is Safe and Increases B-cell Depletion by Rituximab in CD46 Transgenic Mice and Macaques

We have developed a technology that depletes the complement regulatory protein (CRP) CD46 from the cell surface, and thereby sensitizes tumor cells to complement-dependent cytotoxicity triggered by therapeutic monoclonal antibodies (mAbs). This technology is based on a small recombinant protein, Ad3...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Beyer, Ines, Cao, Hua, Persson, Jonas, Wang, Hongjie, Liu, Ying, Yumul, Roma, Li, Zongyi, Woodle, Douglas, Manger, Ronald, Gough, Michael, Rocha, Diane, Bogue, Jaclyn, Baldessari, Audrey, Berenson, Ronald, Carter, Darrick, Lieber, André
Médium: Artigo
Jazyk:Inglês
Vydáno: Nature Publishing Group 2013
Témata:
Original Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3594032/
https://ncbi.nlm.nih.gov/pubmed/23089733
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/mt.2012.212
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky